Publication Name	World Journal of Gastroenterology
Manuscript ID	33405
Country	Italy

Received	2017-02-07 08:50
Peer-Review Started	2017-02-08 16:18
To Make the First Decision	2017-02-23 09:20
Return for Revision	2017-02-27 11:15
Revised	2017-03-08 20:05
Second Decision	2017-03-17 17:24
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-03-20 16:43
Articles in Press	2017-03-20 16:43
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-03-30 10:27
Publish the Manuscript Online	2017-04-14 18:51

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Potential role of nutraceutical compounds in inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Tiziana Larussa, Maria Imeneo and Francesco Luzza
Funding Agency and Grant Number
Corresponding Author	Francesco Luzza, MD, Professor, Department of Health Sciences, University of Catanzaro “Magna Graecia”, Viale Europa, 88100 Catanzaro, Italy. luzza@unicz.it
Key Words	Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Nutraceuticals; Probiotics; Phytochemicals; Herbals; Functional foods
Core Tip	Current therapies for inflammatory bowel diseases (IBD) include aminosalicylates, azathioprine, corticosteroids and recently clinical management with biologic agents has been implemented. However, safety issue are emerging along with concern about the high cost of these new drugs. Nutraceuticals is a broad term used to describe any product derived from food sources, such as herbal products or vitamins, with extra health benefits beyond the basic nutritional value. Despite few clinical trials in IBD patients, nutraceuticals are generally accepted as safer alternative/supplementation to conventional therapy and the available data support their high potential for therapeutic use in human IBD.
Publish Date	2017-04-14 18:51
Citation	Larussa T, Imeneo M, Luzza F. Potential role of nutraceutical compounds in inflammatory bowel disease. World J Gastroenterol 2017; 23(14): 2483-2492
URL	http://www.wjgnet.com/1007-9327/full/v23/i14/2483.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i14.2483

Full Article (PDF)	WJG-23-2483.pdf
Full Article (Word)	WJG-23-2483.doc
Manuscript File	33405-Review.docx
Answering Reviewers	33405-Answering reviewers.pdf
Audio Core Tip	33405-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	33405-Conflict-of-interest statement.pdf
Copyright License Agreement	33405-Copyright assignment.pdf
Peer-review Report	33405-Peer-review(s).pdf
Scientific Misconduct Check	33405-Scientific misconduct check.pdf
Scientific Editor Work List	33405-Scientific editor work list.pdf